Collaborative Research and License Agreements - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended			9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Sep. 30, 2023	Sep. 30, 2022
Research And Development Arrangement Contract To Perform For Others [Line Items]
Common stock shares purchased	7,840,909	3,802,144
Proceeds from issuance of common stock	$ 162,000	$ 81,200		$ 0	$ 19,427
Collaboration receivable	$ 3,474			3,407
Incyte Agreement [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Common stock shares purchased		1,421,523
Purchase price per share		$ 24.62
Proceeds from issuance of common stock		$ 35,000
Collaboration receivable				6,600
Collaboration expense due to counterparty				$ 3,200
Incyte Agreement [Member] \| Maximum [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Potential milestone payments to be made			$ 220,000
Commercialization milestones and tiered royalties			$ 230,000
Incyte Agreement [Member] \| Non-Refundable Cash Payments [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront milestone payable		$ 117,000
Global and U.S. [Member] \| Incyte Agreement [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Development costs associated with clinical trials			45.00%
Global and U.S. [Member] \| Incyte Agreement [Member] \| Incyte Corporation [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Development costs associated with clinical trials			55.00%
Ex-U.S. Countries [Member] \| Incyte Agreement [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Development costs associated with clinical trials			100.00%